Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cosmo NVXSWX:CMHC -2.89%81 Cash-to-Debt is 45.12 as of Jun. 2026, which is 205% above its 10-year median of 14.78. GuruFocus rates XSWX:CMHC with a GF Score™ of 81/100 and a GF Value™ of CHF40.77 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 982 Drug Manufacturers companies, Cosmo NV ranks better than 85.64% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Cosmo NV's cash to debt ratio for the quarter that ended in Jun. 2026 was 45.12.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Cosmo NVcould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Cosmo NV's Cash-to-Debt or its related term are showing as below:
XSWX:CMHC'
s Cash-to-Debt Range Over the Past 10 Years
Min: 1.21 Med: 14.78 Max: 91.69
Current: 45.12
During the past 13 years, Cosmo NV's highest Cash to Debt Ratio was 91.69. The lowest was 1.21. And the median was 14.78.
XSWX:CMHC's Cash-to-Debt is ranked better than 85.64% of 982
companies
in the Drug Manufacturers industry
Industry Median: 0.98
vs XSWX:CMHC: 45.12
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Cosmo NV Cash-to-Debt Related Terms
Cosmo NV Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Cosmo NV's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
XSWX:CMHC vs LLY, JNJ, ABBV: Cash-to-Debt Comparison
For the Drug Manufacturers - General subindustry, Cosmo NV's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosmo NV Cash-to-Debt vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cosmo NV's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Cosmo NV's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cosmo NV (XSWX:CMHC) has a Cash-to-Debt of 45.12 as of Jun. 2026. This is 205% above median its historical median of 14.78. Over the past decade, Cosmo NV's Cash-to-Debt has ranged from 1.21 to 91.69. According to the industry distribution chart, Cosmo NV ranks #141 out of 982 companies in the Drug Manufacturers industry, placing it in the top 14.4%.
Is Cosmo NV's Cash-to-Debt too high?
Cosmo NV's current Cash-to-Debt of 45.12 is 205% above median its 10-year median of 14.78. Over the past 10 years, this metric has ranged from a low of 1.21 to a high of 91.69. The Drug Manufacturers industry median Cash-to-Debt is 0.98. Cosmo NV's value of 45.12 is 4504.1% above this industry median. Based on the distribution chart, Cosmo NV ranks #141 out of 982 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Cosmo NV has a GF Score™ of 81/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cosmo NV's Cash-to-Debt compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Cosmo NV ranks #141 out of 982 companies for Cash-to-Debt. This places Cosmo NV in the top 14% of its industry — outperforming the majority of peers. The industry median Cash-to-Debt is 0.98. Cosmo NV's value of 45.12 is 4504.1% above this benchmark. Historically, Cosmo NV's own Cash-to-Debt has ranged from 1.21 to 91.69 over the past decade. While the company's 10-year median is 14.78 vs. the industry median of 0.98, Cosmo NV has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Drug Manufacturers company?
The median Cash-to-Debt among Drug Manufacturers companies is 0.98, based on 982 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cosmo NV's current Cash-to-Debt of 45.12 is 4504.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Cash-to-Debt is 0.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cosmo NV's current Cash-to-Debt is 45.12, which is 205% above median its own 10-year median of 14.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosmo NV stock overvalued right now?
Based on GuruFocus' analysis, Cosmo NV (XSWX:CMHC) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF40.77, compared to a current price of CHF57.10 — trading 40.1% above its estimated fair value. The current Cash-to-Debt is 45.12, which is 205% above median its 10-year median of 14.78 and 4504.1% above the Drug Manufacturers industry median of 0.98. Cosmo NV's overall GF Score™ is 81/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Cosmo NV (XSWX:CMHC), the current Cash-to-Debt is 45.12 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cosmo NV (XSWX:CMHC) Overvalued in 2026?
Based on GuruFocus' analysis, Cosmo NV stock appears to be overvalued.
The current stock price of CHF57.10 is trading 40.1% above its estimated GF Value™ of CHF40.77.
GuruFocus considers Cosmo NV to be Significantly Overvalued.
Key valuation signals for XSWX:CMHC:
Cash-to-Debt: 45.12 (205% above median its 10-year median of 14.78)
GF Value™: CHF40.77 vs. price of CHF57.10 (40.1% above fair value)
Industry Position: 4504.1% above the Drug Manufacturers median (#141 of 982)
No single metric tells the full story. See the XSWX:CMHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cosmo NV is is a life sciences company. The company is focused on MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing (CDMO). The company designs, develops, and manufactures solutions to address critical medical needs. Its technologies are trusted by international pharmaceutical and MedTech companies and reach patients and healthcare providers around the world. The product pipeline includes Eleview, GI Genius, Winlevi, Lialda, Uceris, and others.
81GF Score
Get the complete analysis for XSWX:CMHC
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:CMHC has been successfully added to your 
